NCT07010484

Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 149 (estimated)
• Sponsor: Kresten Krarup Keller · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Polymyalgia rheumatica (PMR) is the most common chronic inflammatory rheumatic disease among the elderly and is characterized by proximal extremity pain and fatigue. Treatment with prednisolone carries several significant adverse effects, and it is therefore essential to avoid unnecessary treatment. However, clinical diagnosis and even imaging such as positron emission tomography and computed tomography (PET/CT) has low diagnostic accuracy, which decrease after start of prednisolone. The purpose is to evaluate a new method to diagnose PMR with PET/CT using magnetic resonance imaging (MRI) for informing the interpretation of PET in 111 patients suspected of PMR at baseline and after 8 weeks prednisolone treatment. In addition, a treatment initiation strategy guided by clinical diagnosis combined with PET will be evaluated in 100 patients with newly diagnosed PMR.

Conditions

• Polymyalgia Rheumatica (PMR)

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	PET/MRI	PET/MRI at baseline and week 8
DIAGNOSTIC_TEST	PET/CT with 18-FDG	PET/CT in patients not receiving PET/MRI

Timeline

• Start date: 2025-08-21
• Primary completion: 2028-08-31
• Completion: 2032-08-31
• First posted: 2025-06-08
• Last updated: 2025-10-01

Locations

7 sites across 1 country: Denmark